Recent cross-sectional analyses have found that refractory hypertension is rare, with a prevalence of 5% to 10% of patients referred to hypertension specialty clinics for uncontrolled hypertension. [2] [3] [4] Patients with refractory hypertension are more likely to be of African descent and female, compared with patients with controlled RHTN or controlled nonresistant hypertension.
R esistant hypertension (RHTN) is defined as uncontrolled blood pressure (BP), despite the use of effective doses of ≥3 different classes of antihypertensive medications, including a diuretic. Controlled RHTN refers to patients whose BP is controlled with use of ≥4 antihypertensive agents. 1 Recently, the term refractory hypertension has been applied to an extreme phenotype of antihypertensive treatment failure defined as lack of BP control in spite of the use of ≥5 antihypertensive medications. Typically, these patients are treated with maximal recommended doses of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, a calcium channel blocker (typically amlodipine), a thiazide-type diuretic (typically chlorthalidone), and an aldosterone antagonist (spironolactone or eplerenone). Other medications that may be used include combined α-and β-antagonists (eg, labetalol), centrally acting α2-adrenergic agonists (eg, clonidine or guanfacine), and direct vasodilators (eg, minoxidil or hydralazine). Loop diuretics are usually reserved for patients with clinical evidence of fluid retention, advanced chronic kidney disease, or heart failure.
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Methods
Study Population
Consecutive patients were prospectively recruited between April 2014 and March 2017 from those referred to the University of Alabama at Birmingham Hypertension Clinic for uncontrolled RHTN. The patients were evaluated for secondary causes of hypertension, including hyperaldosteronism, pheochromocytoma, and renal artery stenosis as clinically indicated. Patients were eligible for enrollment if their automated office BP (AOBP) remained elevated ≥135/85 mm Hg after having been seen by a hypertension specialist for a minimum of 3 follow-up visits and after having been prescribed at least 5 antihypertensive agents from different classes, including chlorthalidone and spironolactone. Exclusions included patients with suspected nonadherence based on self-report or low medication refill rates, chronic kidney disease stage 4 or 5 (estimated glomerular filtration rate <30 mL/min per 1.73 m2), or pregnancy. The study was approved by the University of Alabama at Birmingham Institutional Review Board, and written informed consent was obtained from all participants.
AOBP Measurement
AOBP was measured after at least 5 minutes of quiet rest in a sitting position with the back supported and the arm supported at heart level. 8 The office BP was measured using the BpTRU device, which automatically obtains 6 serial BP readings, 1 minute apart, before displaying the average of the last 5 readings. All BpTRU assessments were unattended, that is, unobserved in clinic. [9] [10] [11] [12] [13] An appropriately sized cuff was used with a cuff bladder encircling at least 80% of the arm. 13, 14 A BP cutoff of ≥135/85 mm Hg for elevated BP was used based on recent literature validating automated BP devices. 15, 16 Serial, automated, unattended BP measurements, as with the BpTRU device, have been shown to minimize white-coat effects.
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Attended Office BP Measurement
Office BP measurements were also done for all study subjects as part of the research protocol. These assessments were done as a single, attended reading, using an automated device, with the patient seated.
Twenty-Four-Hour ABPM
An automated, noninvasive, oscillometric device (Oscar 2; Suntech Medical Inc, Morrisville, NC) was used to perform ABPM. 18, 19 Recordings were made every 20 minutes during the daytime (awake) and every 30 minutes during the nighttime (asleep) phases of the 24-hour period. Awake and asleep times were determined by patient self-report. All patients were counseled to take all antihypertensive medications during ABPM period. ABPM was determined to be valid if >80% of measurements were successful. Controlled ABPM was defined as mean daytime (awake) BP <135/80 mm Hg, mean 24-hour BP <130/80 mm Hg, and mean nighttime (asleep) BP of 120/70 mm Hg. 18, 19 
Statistical Analysis
Descriptive data are expressed as mean±SD for normally distributed variables and median (interquartile range) for non-normal data. Categorical variables are expressed as number (percent). Data analysis was performed using SAS version 9.3 (SAS Institute Inc; Cary, NC).
Results
Thirty-four subjects were enrolled. Of these, 31 subjects had valid ABPM readings and were included in the final analysis ( Figure 1 ).
Baseline Characteristics
The mean age of the evaluated subjects was 53.7±9.5 years; 70.6% were female and 79.4% were Black. Patients were generally obese with a median body mass index of 35.3±7.3 kg/m2. Overall, 47.1% of the patients had been diagnosed with diabetes mellitus and 41.2% had known obstructive sleep apnea (Table 1) .
Biochemical Evaluation
Serum electrolytes, creatinine, aldosterone, and plasma renin activity were generally within the normal range (Table 1) .
AOBP Measurement
The mean office BP reading obtained with the BpTRU device after 5-minute rest was 159.0±23.3/94.0±13.8 mm Hg. The mean office heart rate during BpTRU measurement was 75.1±13.3 bpm (Table 1) .
Attended Office BP Measurement
The mean attended BP was 166.4±26.6/99.5±16.5 mm Hg. The mean attended office heart rate was 74.9±15.1 bpm (Table 1) .
White-Coat Effect
Of the 31 evaluated subjects with refractory hypertension, a significant white-coat effect was present in 2 subjects (6.5%) based on an uncontrolled AOBP ≥135/85 mm Hg or office BP measurement ≥140/90 mm Hg and a controlled, awake (daytime) ambulatory BP (ABP) <135/85 mm Hg. The same prevalence of 2 out of 31 subjects was observed if an overall 24-hour ABPM <130/80 mm Hg or asleep (nighttime) ABP <120/70 mm Hg was applied to define out-of-office BP control ( Figure 1 ).
Twenty-Four-Hour ABPM Profiles
The mean awake (daytime) ABP for all participants was 166.6±22.6/95.7±16.5 mm Hg; the mean 24-hour ABP was 162.0±23.3/91.9±15.0 mm Hg, and the mean asleep (nighttime) ABP was 154.3±24.5/85.3±15.1 mm Hg (Table 2 ). Of the 31 evaluated patients with refractory hypertension, 29 (93.5%) had nocturnal hypertension, that is, asleep (nighttime) Figure 1 . Schematic of enrolled study participants. ABPM indicates ambulatory blood pressure monitoring.
ABP ≥120/70 mm Hg. Patients were also analyzed for dipping patterns. Dipping was defined as a decrease in BP exceeding 10% of mean daytime values during sleep. 20 There are 4 dipping categories for calculating systolic BP (SBP) dipping, that is, 1−nighttime SBP/(daytime SBP)×100. The categories are reverse dippers <0%, nondippers 0% to 10%, dippers 10% to 20%, and extreme dippers >20%. 21 In the current study, 9 patients (29%) had nocturnal dipping >10%. Of these, 7 patients or 22.5% were dippers and 2 or 6.5% had extreme dipping. Twenty-two patients or 71% had a nondipping pattern. Of these, 18 patients or 58.1% were nondippers; 4 patients or 12.9% had a higher nocturnal BP than daytime BP (ie, reverse dipping; Table 2 ). ABP measurements were further characterized by specific times to evaluate surges of BP. The mean SBP for the evening period (eg, 2-hour average of four 30-minute BP readings before going to sleep) was 167.6±27.7 mm Hg. The lowest asleep SBP (eg, 1-hour average of the 3 BP readings centered on the lowest nighttime reading) averaged 142.4±24.5 mm Hg. Preawake BP (eg, 2-hour average of 4 BP readings just before wake-up) was 162.1±31.9 mm Hg, and prerising supine BP (BP in a supine position <30 minutes before rising) was 149.1±31.6 mm Hg, and the morning SBP on rising was 163.2±29.9 mm Hg. SBP for the 2 hours (average of four 30-minute BP readings) just after waking (eg, morning BP) was 164.3±26.6 mm Hg.
Surges of BP are summarized in Table 2 . The sleep-trough surge defined as the morning BP minus the lowest asleep BP [22] [23] [24] [25] was 21.6±19.7 mm Hg. The prewaking surge defined as the morning BP minus prewake BP 22-24 was 4.3±16.5 mm Hg. Rising BP surge defined as the morning BP on rising minus prerising supine BP was 7.9±16.5 mm Hg. 26 The evening SBP was higher than the morning SBP with a difference of 2.8±21.7 mm Hg (Table 2 and Figure 2 ).
Discussion
This is the first study to report the prevalence of white-coat effect in patients with refractory hypertension, that is, patients failing maximum antihypertensive treatment. The results are unexpected in that a significant white-coat effect is largely absent from this group of patients in contrast to the high prevalence of a white-coat effect in patients with RHTN and in the general hypertensive population. We also report a higher prevalence of nondipping nocturnal BP in patients with refractory hypertension than in patients with RHTN (71% versus 65%, respectively). 27 The current findings demonstrate that refractory hypertension, as a phenotype, is distinct from RHTN by ABPM measurement. Patients with refractory hypertension have a consistently high office and out-of-office BP levels, including nocturnal hypertension (93.5%).
A prominent white-coat effect is common among patients with RHTN, with a prevalence of 20% to 40%. In a crosssectional study, Muxfeldt et al 28 reported the prevalence of white-coat effect in RHTN as 37%. Similarly, de la Sierra et al 5 reported a prevalence rate of white-coat effect of 37.5% in patients with apparent RHTN. Grigoryan et al 29 determined the prevalence of causes of apparent treatment resistance, including white-coat effect, in participants in a study relating BP control to medication adherence. Of the 140 patients with RHTN included in the analysis, 31 (22%) had controlled BP levels during 24-hour ABPM, that is, white-coat effect. In contrast, the white-coat effect was only 6.5% in our study population of patients with refractory hypertension.
Other causes of apparent antihypertensive treatment resistance are nonadherence to prescribed medication, undertreatment, and inaccurate BP measurement. In the Grigoryan study, 20 patients (29%) of the 140 with RHTN were nonadherent with the prescribed medications, 69 patients (49%) were undertreated (receiving less than the maximum doses of prescribed medications), and none were receiving chlorthalidone and spironolactone, the recommended diuretic combination for treating uncontrolled RHTN. 29, 30 Further Jung et al 31 determined medication adherence among 108 patients referred to a hypertension specialty clinic for RHTN by measuring levels of antihypertensive drugs or their metabolites by liquid chromatography-mass spectrometry. After screening out patients with suspected nonadherence, 17 (15%) patients with white-coat effect and 15 (14%) with secondary causes of hypertension, 76 patients were tested. Of those, 40 (53%) were determined to be nonadherent, including 23 patients (30%) who were taking none of their prescribed medications. Azizi et al, 32 in a similar fashion, determined medication adherence in 85 people with RHTN participating in the DENERHTN trial (Renal Denervation for Hypertension). Based on the measurement of urinary drug or drug metabolite levels, only 50% of the participants were adherent with the provided medicines at 6 months of follow-up.
Undertreatment is also widespread among patients with apparent RHTN. Egan et al 33 assessed antihypertensive regimens in a large network of primary care clinics in the Southeastern United States. Of the over 44 000 patients with RHTN, only 15% were determined to have been prescribed optimal antihypertensive regimens, including a diuretic and 2 other medications at ≥50% of the maximum recommended dose. By requiring maximum tolerated doses of 5 different medication classes, which specifically includes chlorthalidone and spironolactone, our study design excluded patients who may have been undertreated. While physician-related treatment inertia can expand the RHTN group, it would not have contributed to the occurrence of refractory hypertension.
Inaccurate BP measurement can contribute to mislabeling BP control in the office. However, the current study limits this effect by performing rigorous office BP assessments. BP measurements were made according to guidelines and with a collection of unattended, serial BP readings using the BpTRU device. 15, 16 Taken together with the ABPM measurements, nearly all refractory patients had true uncontrolled hypertension, both in and outside of the clinic.
Unattended AOBP measurements without a rest period and daytime ABP values have generally been reported to be similar or with the former being slightly lower. 34, 35 In contrast, unattended systolic AOBP measurements obtained after a rest period, as done in the current study, have been reported to be 7 to 9 mm Hg below daytime ambulatory values. 12, 36, 37 This is consistent with the current findings, in that unattended, automated SBP values were, on average, 7.6 mm Hg lower than the daytime ambulatory SBP values. However, when office BP values (single, attended measurements) were used as the reference BP levels, the prevalence of a prominent white-coat effect was the same as with the unattended readings. Therefore, the current findings indicate that patients with refractory hypertension generally have sustained BP levels in and outside of the clinic, regardless of whether the clinic BP measurements were done attended or unattended.
Unknown is the degree of medication adherence in our study population. Poor adherence is a common cause of pseudoresistance and could account for the high prevalence of uncontrolled BP by ABPM in our population. In the current study, adherence was monitored by patient self-report and medication refill rates, but clearly, true determination of adherence will require detection of urinary or plasma drug or drug metabolite levels, as has been done in patients with RHTN.
In addition to high awake BPs by ABPM, this cohort of patients with refractory hypertension had high nighttime BP levels, with 93.5% meeting criteria for nocturnal hypertension. Nighttime dipping was seen in only 29% of patients with refractory hypertension, which is substantially lower than the 50% to 60% prevalence of nocturnal dipping typically observed in patients with RHTN. 38, 39 Nondipping has been attributed to failure to suppress nighttime sympathetic output. 40 Such an effect in patients with refractory hypertension would be consistent with the findings of Dudenbostel et al, 4 which recently provided evidence of heightened sympathetic activity in patients with refractory hypertension, including at night. As refractory patients have higher nondipping pattern and nocturnal hypertension, they tend to manifest a lower morning BP surge. In addition to the sustained out-ofoffice BP levels typifying refractory hypertension, that is, the absence of white-coat effects, lack of normal nocturnal BP dipping would further increase cardiovascular risk in this group of patients.
As has been observed previously, patients with refractory hypertension were predominantly black and female. Although speculative, antihypertensive treatment failure may be related, in at least in part, to socioeconomic issues, including socioeconomic stressors, unique to these subgroups that increase sympathetic output and worsen treatment resistance. Prospective studies are needed to evaluate this possibility.
Strengths of the current study include careful evaluation of all patients to rule out secondary causes of hypertension; treatment of patients by hypertension specialists with ≥5 antihypertensive medications at maximal tolerated doses; rigorous assessment of AOBP levels based on serial, unobserved BP measurements; and use of 24-hour APBM for determination of out-of-clinic BP levels. Study weaknesses include the relatively small cohort size and lack of determination of medication adherence by measurement of urinary or plasma drug or drug metabolites.
Perspectives
A significant white-coat effect is largely absent from patients with refractory hypertension based on careful AOBP measurements. The higher prevalence of nocturnal hypertension confirms that refractory hypertension is a phenotype of sustained antihypertensive treatment failure, both in and out of the office and during daytime and nighttime. Such continuous lack of BP control portends increased cardiovascular risk and may reflect mechanisms of antihypertensive treatment failure different from patients presenting with RHTN, but whose BP can be controlled.
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